Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death, the company said.

Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment when your lung cancer: is a type called “extensive-stage small cell lung cancer,” which ...

Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety ...

The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer immunotherapy. The treatment offers a quicker and more comfortable ...

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved Tecentriq Hybreza™, the first and only PD- 1 inhibitor for subcutaneous, under the ...

With Tecentriq Hybreza and Roche/Genentech’s 13 other subcutaneous therapies – available across various diseases – we offer additional administration options to meet the diverse preferences ...

Tecentriq is a prescription drug used to treat certain forms of cancer. Learn about the drug’s dosages, form, strength, and more.